An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum...

Area of Science:

• Oncology
• Immunotherapy
• Gynecologic Oncology

Background:

• Advanced endometrial cancer often lacks effective treatment options after progression on platinum-based chemotherapy.
• Immunotherapy, specifically anti-PD-1/PD-L1 antibodies, is emerging as a promising treatment modality.
• Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors are particularly responsive to PD-1 blockade.

Observation:

• This case report details a patient with advanced, platinum-refractory endometrial cancer.
• The patient's tumor was characterized by high disease burden and mismatch repair deficiency (dMMR).

Findings:

• The patient received dostarlimab, an anti-PD-1 monoclonal antibody.
• An exceptional and rapid treatment response was observed with dostarlimab therapy.

Implications:

• Dostarlimab demonstrates significant potential as a therapeutic option for a subset of advanced endometrial cancer patients.
• This finding supports the role of immunotherapy in mismatch repair deficient gynecologic malignancies.
• Further research into PD-1 blockade in endometrial cancer is warranted.